Advancing the Management of Cholestatic Liver Disease: Optimizing Treatment Pathways and Emerging Therapies | AASLD

Advancing the Management of Cholestatic Liver Disease: Optimizing Treatment Pathways and Emerging Therapies

Nov 09 2025
Convention Center: Room 152, Level 1
12:30 PM - 2:00 PM

Description

In this activity, experts in adult and paediatric hepatology and gastroenterology explore practical strategies and evidence-based tools to diagnose and facilitate tailored treatment decision-making for primary biliary cholangitis (PBC) and progressive familial intrahepatic cholestasis (PFIC).  Supported by: Ipsen Biopharmaceuticals, Inc.  Organized by: PeerVoice CME Provider: USF Health  Link: https://cme.peervoice.com/140202451_1/140202451_1_p1/stage1reg?CountryID=US&ProjectNumber=140202451_1 Important Note: Continuing education credits for Satellite Symposia are offered by the sponsoring organizations. These sessions are not accredited by AASLD.

Journey Maps

Objectives

  • Utilise practical approaches, including evidence-based tools, to evaluate and predict response to therapy and facilitate treatment decision-making in patients with cholestatic liver disease.
  • Appraise the data from trials and studies examining the safety and efficacy of therapies in primary biliary cholangitis (PBC) and progressive familial intrahepatic cholestasis (PFIC).
  • Implement evidence-based treatment strategies to optimise clinical and patient-related outcomes in the management of PBC and PFIC. Describe the clinical presentation and biochemical abnormalities in patients with PBC and PFIC.